The idea of harnessing the host’s immune system to eliminate cancer is not new. Immunotherapy has transformed the treatment of cancers like advanced melanoma with immune checkpoint inhibitors. But not all cancers respond to immunotherapy, limiting its widespread adoption.

Cancer cell reprogramming has emerged as a promising strategy for immunotherapy. Cellular reprogramming of cancer cells to antigen presenting cells can be highly efficient for treating some cancers.

In this webinar, Dr. Filipe Pereira, Professor of Molecular Medicine at Lund University, Cofounder and Head of Innovation at Asgard Therapeutics, talks about the transformative potential of a cancer therapy based on direct cell reprogramming.